Paulo Rodrigues-Santos is the Head of Research and Science Communication at the Institute of Immunology, Invited Assistant at the Faculty of Medicine and Director of the Immunology and Oncology Laboratory of the Center for Neuroscience and Cell Biology, University of Coimbra (Portugal).
PRS developed his work on Immunogenetics under the supervision of Professor Gottfried Mauff at Institute for Medical Microbiology and Hygiene, Faculty of Medicine, University of Cologne, Germany. He worked on Transplantation Immunobiology as Head of the Functional Genomics Laboratory at the Center for Histocompatibility of the Centre (Coimbra, Portugal). PRS was Chair of the Education Committee of the European Federation for Immunogenetics (EFI), Board Member of the European Complement Network (ECN) and Vice-President of the Portuguese Society for Immunology (SPI). He is Founder and Coordinator of the Portuguese Group of Immuno-Oncology (gpI-O), a joint working group of the Portuguese Society for Oncology (SPO) and the Portuguese Society for Immunology (SPI). ORCID: 0000-0001-7519-1620 Scopus: 37021720200 ResearchID: M-3175-2013 Loop profile: 55546 Ciência ID: 4311-1E7F-9AA8 Lab membersJani Sofia Almeida
PhD student Health Sciences Fac Medicine, Univ Coimbra Luana Madalena Sousa
PhD student Health Sciences Fac Medicine, Univ Coimbra Immunology & Oncology Laboratory Center for Neurosciences & Cell Biology Univ Coimbra Syeda Munnawara Fatima
MSc Student Biomedical Research Fac Medicine, Univ Coimbra Immunology & Oncology Laboratory Center for Neurosciences & Cell Biology Univ Coimbra Daniela Marques Silva
BSc Student Biochemistry Fac Sciences and Technology, Univ Coimbra Immunology & Oncology Laboratory Center for Neurosciences & Cell Biology Univ Coimbra |
5th SICR & SPI Annual Meeting 20245th SICR-Symposium on Immunomodulation in Cancer and Regeneration
April 16th, 2024. Porto, Portugal. More info The XLIX Annual Meeting of the Portuguese Society for Immunology (SPI) will take place in Porto at Fundação Engenheiro António de Almeida. April 17th to 19th, 2024. Porto, Portugal. More info SAVE THE DATE: gpI-O
|
CALL FOR PAPERS
Frontiers in OncologySpecial Issue
"Peripheral Blood-Based Biomarkers for Immune Monitoring of Cancer and Cancer Therapy" Guest Editors: Paulo Rodrigues Santos, José Manuel Casanova & Raquel Tarazona More info |
International Journal of Molecular SciencesSpecial Issue
"Innate and Innate-Like Lymphoid Cells: New Populations and Old Tricks" Guest Editor: Paulo Rodrigues Santos More info |
Frontiers in AgingNew Research Topic
"Rising Stars in Aging and the Immune System 2023" Guest Editors: Paulo Rodrigues Santos & Beatriz Martin-Antonio More info |
RECENT PUBLICATIONS
INNATE IMMUNITY AND PARKINSON DISEASE
Indoleamine 2,3-dioxygenase (IDO1) – can dendritic cells and monocytes expressing this moonlight enzyme change the phase of Parkinson’s Disease?
Gonçalves M , Rodrigues-Santos P, Januário C, Cosentino M, Pereira FC.
Int Immunopharmacol 2024 (in press).
Impact factor: 5.600 Q1 (Pharmacology)
Indoleamine 2,3-dioxygenase (IDO1) – can dendritic cells and monocytes expressing this moonlight enzyme change the phase of Parkinson’s Disease?
Gonçalves M , Rodrigues-Santos P, Januário C, Cosentino M, Pereira FC.
Int Immunopharmacol 2024 (in press).
Impact factor: 5.600 Q1 (Pharmacology)
INNATE IMMUNITY REGULATION
A peripheral blood mononuclear cell-based in vitro model: a tool to explore indoleamine 2, 3-dioxygenase-1 (IDO1)
Gonçalves M , Furgiuele A, Rasini E, Legnaro M, Ferrari M, Luini A, Rodrigues-Santos P, Caramelo F, Marino F, Pereira FC, Cosentino M.
Eur J Pharmacol 2024;968:176420.
doi:10.1016/j.ejphar.2024.176420
Impact factor: 5.000 Q1 (Pharmacology)
A peripheral blood mononuclear cell-based in vitro model: a tool to explore indoleamine 2, 3-dioxygenase-1 (IDO1)
Gonçalves M , Furgiuele A, Rasini E, Legnaro M, Ferrari M, Luini A, Rodrigues-Santos P, Caramelo F, Marino F, Pereira FC, Cosentino M.
Eur J Pharmacol 2024;968:176420.
doi:10.1016/j.ejphar.2024.176420
Impact factor: 5.000 Q1 (Pharmacology)
IMMUNE INNATE-LIKE LYMPHOID CELLS IN DISEASE
Natural Killer T-like cells: immunobiology and role in disease
Almeida JS, Casanova JM, Santos-Rosa M, Tarazona R, Solana R, Rodrigues-Santos P.
Int J Mol Sci 2023, 24(3), 2743.
doi: 10.3390/ijms24032743
Impact factor: 6.208 Q1 (Medicine - Miscelaneous)
Natural Killer T-like cells: immunobiology and role in disease
Almeida JS, Casanova JM, Santos-Rosa M, Tarazona R, Solana R, Rodrigues-Santos P.
Int J Mol Sci 2023, 24(3), 2743.
doi: 10.3390/ijms24032743
Impact factor: 6.208 Q1 (Medicine - Miscelaneous)
IMMUNE CELLS AND TUMOR MARKERS IN OSTEOSARCOMA
Tumor-infiltrating lymphocytes and cancer markers in osteosarcoma: influence on patient survival
Casanova JM, Almeida JS, Reith J, Sousa LM, Fonseca R, Freitas-Tavares P, Santos-Rosa M, and Rodrigues-Santos P.
Cancers 2021, 13(23), 6075.
doi: 10.3390/cancers13236075
Impact factor: 6.639 Q1 (Oncology)
Tumor-infiltrating lymphocytes and cancer markers in osteosarcoma: influence on patient survival
Casanova JM, Almeida JS, Reith J, Sousa LM, Fonseca R, Freitas-Tavares P, Santos-Rosa M, and Rodrigues-Santos P.
Cancers 2021, 13(23), 6075.
doi: 10.3390/cancers13236075
Impact factor: 6.639 Q1 (Oncology)
IMMUNE STATUS IN SOFT TISSUE SARCOMA
The role of Natural Killer cells in Soft Tissue Sarcoma: prospects for immunotherapy
Fortes-Andrade T, Almeida JS, Sousa LM, Santos-Rosa M, Freitas-Tavares P, Casanova JM, Rodrigues‑Santos P.
Cancers 2021, 13(15), 3865.
doi: 10.3390/cancers13153865
Impact factor: 6.639 Q1 (Oncology)
The role of Natural Killer cells in Soft Tissue Sarcoma: prospects for immunotherapy
Fortes-Andrade T, Almeida JS, Sousa LM, Santos-Rosa M, Freitas-Tavares P, Casanova JM, Rodrigues‑Santos P.
Cancers 2021, 13(15), 3865.
doi: 10.3390/cancers13153865
Impact factor: 6.639 Q1 (Oncology)
Tumor and peripheral immune status in Soft Tissue Sarcoma: implications for immunotherapy
Sousa LM, Almeida JS, Fortes-Andrade T, Santos-Rosa M, Freitas-Tavares P, Casanova JM, Rodrigues‑Santos P.
Cancers 2021, 13(15), 3885.
doi: 10.3390/cancers13153885
Impact factor: 6.639 Q1 (Oncology)
Sousa LM, Almeida JS, Fortes-Andrade T, Santos-Rosa M, Freitas-Tavares P, Casanova JM, Rodrigues‑Santos P.
Cancers 2021, 13(15), 3885.
doi: 10.3390/cancers13153885
Impact factor: 6.639 Q1 (Oncology)
IMMUNODYNAMIC MONITORING IN CANCER IMMUNOTHERAPY
Immunotherapy and predictive immunologic profile: the tip of the iceberg
Cunha Pereira T, Rodrigues‑Santos P, Almeida JS, Rêgo Salgueiro F, Monteiro AR, Macedo F, Félix Soares R, Domingues I, Jacinto P, Sousa G
Medical Oncology 2021, 38:51.
doi: 10.1007/s12032-021-01497-8
Impact factor: 3.064 Q2 (Oncology)
Immunotherapy and predictive immunologic profile: the tip of the iceberg
Cunha Pereira T, Rodrigues‑Santos P, Almeida JS, Rêgo Salgueiro F, Monteiro AR, Macedo F, Félix Soares R, Domingues I, Jacinto P, Sousa G
Medical Oncology 2021, 38:51.
doi: 10.1007/s12032-021-01497-8
Impact factor: 3.064 Q2 (Oncology)